Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)-Reference-Cited by-同舟云学术

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Published:2011-08-18 Issue:18 Volume:54 Page:6342-6363
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cui J. Jean¹,Tran-Dubé Michelle¹,Shen Hong¹,Nambu Mitchell¹,Kung Pei-Pei¹,Pairish Mason¹,Jia Lei¹,Meng Jerry¹,Funk Lee¹,Botrous Iriny¹,McTigue Michele¹,Grodsky Neil¹,Ryan Kevin¹,Padrique Ellen¹,Alton Gordon¹,Timofeevski Sergei¹,Yamazaki Shinji¹,Li Qiuhua¹,Zou Helen¹,Christensen James¹,Mroczkowski Barbara¹,Bender Steve¹,Kania Robert S.¹,Edwards Martin P.¹

Affiliation:

1. La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm2007613

Reference64 articles.

1. The discovery of receptor tyrosine kinases: targets for cancer therapy

2. Tyrosine Kinases as Targets for Cancer Therapy

3. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

4. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

Cited by 774 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sonochemical replacement of C-3 hydrogen of indole by a pyridine ring: Docking, synthesis and in vitro evaluation of 3-(6-aryl pyridin-2-yl)indoles against SIRT1;Journal of Molecular Structure;2024-02

2. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27

3. Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation;Acta Neuropathologica;2024-01-24

4. Structural Aspects of the ROS1 Kinase Domain and Oncogenic Mutations;Crystals;2024-01-23

5. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23